New price cuts in Spain will "strangle" pharmaceutical industry
This article was originally published in Scrip
Executive Summary
The pharmaceutical industry in Spain is shocked and appalled at new austerity measures in Spain that will introduce yet more price cuts, obligatory prescribing by active ingredient, a reorganisation of the reference pricing system and new ways of determining which drugs to reimburse. They will further risk the future of local companies and SMEs, says Farmaindustria, which represents the R&D-based pharmaceutical industry.